Kymera Therapeutics, Inc.

• Kymera Therapeutics to report Q3 2026 financial results on October 29, 2026
  Pluang · 22 Oct 2026
• Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
  StreetInsider · 22 Oct 2026
• Kymera Therapeutics (NDQ:KYMR) Has Proven It Can Destroy Proteins. Can It Build Blockbuster Medicines?
  Stocks Down Under · 22 Oct 2026
• Form 144 Kymera Therapeutics For: 19 October By Investing.com
  Investing.com India · 19 Oct 2026
• Raymond James sets USD 140 target for Kymera Therapeutics stock
  ad-hoc-news.de · 16 Oct 2026
• Raymond James set a USD 140.00 target for Kymera Therapeutics stock
  ad-hoc-news.de · 14 Oct 2026
• Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon
  Seeking Alpha · 09 Oct 2026
• Kymera Therapeutics (NASDAQ:KYMR) Stock Falls 5% - Should You Sell?
  MarketBeat · 06 Oct 2026
• Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Company Stock
  MarketBeat · 01 Oct 2026
• Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
  Morningstar · 30 Sep 2026
• Goldman Sachs resumes Kymera Therapeutics stock coverage
  Investing.com · 24 Sep 2026
• Kymera Therapeutics at Stifel forum: faster path for lead drug By Investing.com
  Investing.com UK · 24 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →